@article{b71d05d9dfd545e98272c4c4d84366bd,
title = "Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization",
abstract = "Liu et al. isolated 50 escape mutants to 19 monoclonal antibodies targeting the SARS-CoV-2 spike using a VSV-SARS2 chimera. Some mutants (S477N) resist neutralization by multiple mAbs, and others (E484K) are less sensitive to neutralization by convalescent sera. Several mutants exist in clinical SARS2-CoV-2 isolates and thus warrant further study.",
keywords = "ACE2 receptor decoys, COVID-19 vaccines, SARS-CoV-2 escape mutants, convalescent sera, coronaviruses, monoclonal antibodies, receptor-binding domain",
author = "Zhuoming Liu and VanBlargan, {Laura A.} and Bloyet, {Louis Marie} and Rothlauf, {Paul W.} and Chen, {Rita E.} and Spencer Stumpf and Haiyan Zhao and Errico, {John M.} and Theel, {Elitza S.} and Liebeskind, {Mariel J.} and Brynn Alford and Buchser, {William J.} and Ellebedy, {Ali H.} and Fremont, {Daved H.} and Diamond, {Michael S.} and Whelan, {Sean P.J.}",
note = "Funding Information: This study was supported by NIH contracts and grants (75N93019C00062, R01 AI127828, R01 AI157155, and R37 AI059371), the Defense Advanced Research Project Agency (HR001117S0019), and gifts from Washington University in Saint Louis. Z.L. designed and performed the experiments. L.A.V. generated and validated all hybridoma-produced mAbs. P.W.R. L.-M.B. R.E.C. S.S. and B.A. provided experimental assistance. M.J.L. and W.J.B. set up the high-throughput assay. H.Z. and D.H.F. generated and provided purified ACE2 proteins. J.M.E. mapped escape mutant. E.S.T. identified and provided the human immune serum. A.H.E. generated and provided cloned versions of mAbs. Z.L. M.S.D. and S.P.J.W. analyzed data. Z.L. L.A.V. M.S.D and S.P.J.W. wrote the initial draft, with the other authors providing editing comments. M.S.D. is a consultant for Inbios, Vir Biotechnology, and NGM Biopharmaceuticals, and is on the scientific advisory board of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. The Ellebedy laboratory has received unrelated funding support in sponsored research agreements from Emergent BioSolutions, and funding support in sponsored research agreements from AbbVie to further develop 2B04 and 2H04 as therapeutic mAbs. A.H.E. and Washington University have filed a patent application that includes the SARS-CoV-2 antibodies 2B04 and 2H04 for potential commercial development. S.P.J.W. and Z.L. have filed a disclosure with Washington University for VSV-SARS-CoV-2 mutants to characterize antibody panels. S.P.J.W. and Washington University have filed a patent application on VSV-SARS-CoV-2. S.P.J.W has received unrelated funding support in sponsored research agreements with Vir Biotechnology, AbbVie, and sAB therapeutics. Funding Information: This study was supported by NIH contracts and grants ( 75N93019C00062 , R01 AI127828 , R01 AI157155 , and R37 AI059371 ), the Defense Advanced Research Project Agency ( HR001117S0019 ), and gifts from Washington University in Saint Louis. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = mar,
day = "10",
doi = "10.1016/j.chom.2021.01.014",
language = "English",
volume = "29",
pages = "477--488.e4",
journal = "Cell Host and Microbe",
issn = "1931-3128",
number = "3",
}